Cargando…

Tracking disease progression non‐invasively in Duchenne and Becker muscular dystrophies

BACKGROUND: Analysis of muscle biopsies allowed to characterize the pathophysiological changes of Duchenne and Becker muscular dystrophies (D/BMD) leading to the clinical phenotype. Muscle tissue is often investigated during interventional dose finding studies to show in situ proof of concept and ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spitali, Pietro, Hettne, Kristina, Tsonaka, Roula, Charrout, Mohammed, van den Bergen, Janneke, Koeks, Zaïda, Kan, Hermien E., Hooijmans, Melissa T., Roos, Andreas, Straub, Volker, Muntoni, Francesco, Al‐Khalili‐Szigyarto, Cristina, Koel‐Simmelink, Marleen J.A., Teunissen, Charlotte E., Lochmüller, Hanns, Niks, Erik H., Aartsma‐Rus, Annemieke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104105/ https://www.ncbi.nlm.nih.gov/pubmed/29682908 http://dx.doi.org/10.1002/jcsm.12304

Ejemplares similares

Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy
por: Signorelli, Mirko, et al.
Publicado: (2019)

Multi‐parametric MR in Becker muscular dystrophy patients
por: Hooijmans, Melissa T., et al.
Publicado: (2020)

Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models
por: Tsonaka, Roula, et al.
Publicado: (2020)

Plasma lipidomic analysis shows a disease progression signature in mdx mice
por: Tsonaka, Roula, et al.
Publicado: (2021)

Multiomic characterization of disease progression in mice lacking dystrophin
por: Signorelli, Mirko, et al.
Publicado: (2023)

Diffusion‐tensor magnetic resonance imaging captures increased skeletal muscle fibre diameters in Becker muscular dystrophy
por: Cameron, Donnie, et al.
Publicado: (2023)

Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy
por: Strandberg, Kristin, et al.
Publicado: (2020)

Cross‐sectional serum metabolomic study of multiple forms of muscular dystrophy
por: Spitali, Pietro, et al.
Publicado: (2018)

The neurocognitive profile of adults with Becker muscular dystrophy in the Netherlands
por: Koeks, Zaıda, et al.
Publicado: (2022)

Simultaneous Enrichment Analysis of all Possible Gene-sets: Unifying Self-Contained and Competitive Methods
por: Ebrahimpoor, Mitra, et al.
Publicado: (2019)

Penalized regression calibration: A method for the prediction of survival outcomes using complex longitudinal and high‐dimensional data
por: Signorelli, Mirko, et al.
Publicado: (2021)

Decision-Making And Selection Bias in Four Observational Studies on Duchenne and Becker Muscular Dystrophy
por: Naarding, Karin J., et al.
Publicado: (2020)

Longitudinal Assessment of Creatine Kinase, Creatine/Creatinine(ratio), and Myostatin as Monitoring Biomarkers in Becker Muscular Dystrophy
por: van de Velde, Nienke M., et al.
Publicado: (2023)

Low dystrophin variability between muscles and stable expression over time in Becker muscular dystrophy using capillary Western immunoassay
por: Koeks, Z., et al.
Publicado: (2021)

Selection Approach to Identify the Optimal Biomarker Using Quantitative Muscle MRI and Functional Assessments in Becker Muscular Dystrophy
por: van de Velde, Nienke M., et al.
Publicado: (2021)

Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015)

TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy
por: Spitali, Pietro, et al.
Publicado: (2020)

Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies
por: Ayoglu, Burcu, et al.
Publicado: (2014)

Negative Binomial mixed models estimated with the maximum likelihood method can be used for longitudinal RNAseq data
por: Tsonaka, Roula, et al.
Publicado: (2020)

Baseline fat fraction is a strong predictor of disease progression in Becker muscular dystrophy
por: Veeger, Thom T. J., et al.
Publicado: (2022)

Peripheral blood transcriptome profiling enables monitoring disease progression in dystrophic mice and patients
por: Signorelli, Mirko, et al.
Publicado: (2021)

Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers
por: Johansson, Camilla, et al.
Publicado: (2023)

Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients
por: Capitanio, Daniele, et al.
Publicado: (2020)

Muscle architecture is associated with muscle fat replacement in Duchenne and Becker muscular dystrophies
por: Veeger, Thom T. J., et al.
Publicado: (2021)

Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants
por: van den Bergen, Janneke C, et al.
Publicado: (2015)

Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne
por: Lourbakos, A., et al.
Publicado: (2017)

Pathway testing for longitudinal metabolomics
por: Ebrahimpoor, Mitra, et al.
Publicado: (2021)

Autophagy is Impaired in the Tibialis Anterior of Dystrophin Null Mice
por: Spitali, Pietro, et al.
Publicado: (2013)

The mRNA Binding Proteome of Proliferating and Differentiated Muscle Cells
por: Hiller, Monika, et al.
Publicado: (2020)

An update on Becker muscular dystrophy
por: Straub, Volker, et al.
Publicado: (2023)

Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice
por: Bizot, Flavien, et al.
Publicado: (2022)

Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review
por: Verhaart, Ingrid E. C., et al.
Publicado: (2017)

Good news for the mdx mouse community: Improved dystrophin restoration after skipping mouse dystrophin exon 23
por: Aartsma-Rus, Annemieke
Publicado: (2022)

Givinostat for Becker muscular dystrophy: A randomized, placebo-controlled, double-blind study
por: Comi, Giacomo P., et al.
Publicado: (2023)

The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023)

Characterization of patients with Becker muscular dystrophy by histology, magnetic resonance imaging, function, and strength assessments
por: Comi, Giacomo P., et al.
Publicado: (2021)

Biomarkers of Duchenne muscular dystrophy: current findings
por: Szigyarto, Cristina Al-Khalili, et al.
Publicado: (2018)

Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases
por: Lochmüller, Hanns, et al.
Publicado: (2018)

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_35dkam6so4p01sa5sseipdhpuk